Arctoris Opens Biophysics Center to Tackle the AI-to-Experiment Bottleneck
Arctoris has launched a Biophysics Centre of Excellence aimed at closing the gap between AI predictions and laboratory validation. The move underscores a growing consensus in drug discovery that better models are not enough without high-quality experimental systems to test and refine them.
Arctoris’ new Biophysics Centre of Excellence addresses one of the most persistent problems in AI-enabled drug discovery: the handoff from computational prediction to experimental proof. The field has generated no shortage of models, but many programs still slow down when hypotheses meet the messy reality of assay design, reproducibility, and mechanistic validation.
Biophysics is an especially important layer in that transition. It provides the quantitative measurements that reveal how molecules interact with targets, whether binding is meaningful, and how those interactions may translate into potency or selectivity. By investing in this capability, Arctoris is effectively betting that the future advantage lies not in AI alone but in closed-loop systems where predictions continuously improve through high-quality experimental feedback.
This is an important market signal because it pushes back against the myth of “software-only” drug discovery. The most durable AI platforms are increasingly those that own or tightly control the experimental data generation process. In other words, the real moat may be less about model architecture and more about the infrastructure that creates trustworthy labels and actionable biological insight.
Expect more companies to make similar moves. As AI tools become easier to access, differentiation will likely come from integrated execution: how quickly and reliably a team can move from model output to decision-grade evidence. Arctoris’ expansion fits squarely within that emerging playbook.